NCT00135057已完成3 期
Insulin Glulisine Administered in a Fixed Bolus Regimen Versus Variable Bolus Regimen Based on Carbohydrate Counting in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 281
- 试验地点
- 2
- 主要终点
- Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count
研究概览
简要总结
The purpose of this study is to compare the change in glycemic control, as measured by hemoglobin A1c (HbA1c) from baseline to study week 24, in subjects receiving insulin glulisine as mealtime insulin following a variable bolus insulin regimen (based on carbohydrate counting) versus a fixed bolus insulin regimen, with insulin glargine as basal insulin in both arms of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of type 2 diabetes mellitus for at least six months; 18 to 70 years of age, inclusive.
- •A1c ≥ 7.0% and ≤ 10% at screening
- •At least 3 months of continuous insulin and/or insulin analogue therapy (on at least 2 injections) +/- metformin prior to study entry. (Note: Subjects receiving insulin glargine [Lantus] twice a day [split dose] will be considered as being on one injection only.)
- •Willingness of subject to discontinue other anti-diabetic drug treatments and to remain off them through the entire study
- •Negative glutamic acid decarboxylase (GAD) autoantibodies
- •Ability and willingness to perform self-monitoring of blood glucose (SMBG) at least four times a day, and at least 7 times daily during the 7-point blood glucose (BG) profile measurement days
- •Ability and willingness to adhere to, and be compliant with, the study protocol
- •Must be able to read English at the sixth grade level in order to complete the patient-reported outcomes component of the study.
- •Signed informed consent
排除标准
- •Subjects treated with sulfonylureas, thiazolidinediones (TZDs), or any other oral antidiabetic drugs (within the 3 months before study entry) except for insulin and/or insulin analogues with or without metformin
- •Planned pregnancy; or pregnant or lactating females.
- •For subjects treated with metformin: serum creatinine ≥ 1.5 mg/dL (133 µmol/L) for males or ≥ 1.4 mg/dL (124 µmoL) for females
- •Serum creatinine ≥ 3.0 mg/dL (266 µmol/L)
- •Any clinically significant renal disease (other than proteinuria) or hepatic disease
- •Serum ALT or AST levels greater than 2.5 X the upper limit of normal
- •Any current malignancy or any cancer within the past 5 years (except for adequately treated basal cell skin cancer or cervical carcinoma in situ)
- •Diagnosis of dementia or mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
- •Diagnosis of impaired dexterity or vision rendering the subject unable to administer multiple daily injections (MDIs)
- •Cardiac status New York Heart Association (NYHA) III-IV
- •Hypersensitivity to Lantus or insulin glulisine (Apidra) or any of their components
- •Any disease or condition (including abuse of illicit drugs, prescription medicines or alcohol) that, in the opinion of the investigator or sponsor, may interfere with the completion of the study.
- •Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study
- •Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
结局指标
主要结局
Compare the change in glycemic control (as measured by A1c) from baseline to endpoint of fixed dose bolus regimen vs. variable bolus regimen based on carbohydrate count
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
4 期
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)Type 1 Diabetes MellitusNCT01848990Halozyme Therapeutics456
终止
4 期
Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory ControlDiabetes Mellitus, Type 2NCT00283049Sanofi390
已完成
4 期
Pilot Study of Glycemic Control in Diabetic Hemodialyzed PatientsDiabetes MellitusNCT01828970Centre Europeen d'Etude du Diabete38
已完成
4 期
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT01175811Eli Lilly and Company402
已完成
3 期
Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination TreatmentDiabetes Mellitus, Type 2NCT01336751Sanofi212